Total Payments
$1,002
2024 Payments
$29.96
Companies
10
Transactions
55
Medicare Patients
5,854
Medicare Billing
$855,654
Payment Breakdown by Category
Food & Beverage$1,001 (99.9%)
Education$0.79 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,001 | 54 | 99.9% |
| Education | $0.79 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $335.83 | 33 | $0 (2021) |
| Novo Nordisk Inc | $318.13 | 7 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $111.85 | 1 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $106.65 | 4 | $0 (2024) |
| Amgen Inc. | $46.29 | 3 | $0 (2024) |
| Allergan Inc. | $22.61 | 2 | $0 (2017) |
| AbbVie, Inc. | $22.28 | 1 | $0 (2018) |
| Celgene Corporation | $21.51 | 2 | $0 (2018) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.71 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29.96 | 2 | Amgen Inc. ($15.45) |
| 2023 | $143.48 | 4 | Boehringer Ingelheim Pharmaceuticals, Inc. ($111.85) |
| 2022 | $214.30 | 4 | Novo Nordisk Inc ($122.16) |
| 2021 | $136.85 | 2 | Novo Nordisk Inc ($112.69) |
| 2020 | $144.50 | 8 | PFIZER INC. ($75.15) |
| 2019 | $46.61 | 3 | PFIZER INC. ($46.61) |
| 2018 | $226.11 | 27 | PFIZER INC. ($163.58) |
| 2017 | $59.84 | 5 | PFIZER INC. ($26.33) |
All Payment Transactions
55 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/11/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: Cardiology | ||||||
| 01/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.51 | General |
| Category: Cardio-renal | ||||||
| 10/10/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: Inflammation | ||||||
| 08/01/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $111.85 | General |
| Category: DIABETES | ||||||
| 02/15/2023 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.46 | General |
| Category: Cardiology | ||||||
| 01/20/2023 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Education | In-kind items and services | $0.79 | General |
| Category: UROLOGY | ||||||
| 08/17/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $25.12 | General |
| Category: Cardio-renal | ||||||
| 06/21/2022 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $122.16 | General |
| Category: Diabetes | ||||||
| 03/17/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $32.67 | General |
| Category: Cardio-renal | ||||||
| 01/20/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $34.35 | General |
| Category: Cardio-renal | ||||||
| 06/08/2021 | Novo Nordisk Inc | RYBELSUS (Drug) | Food and Beverage | In-kind items and services | $112.69 | General |
| Category: Diabetes | ||||||
| 05/19/2021 | PFIZER INC. | COLOGUARD DNA CAPTURE REAGENTS (Device) | Food and Beverage | In-kind items and services | $24.16 | General |
| Category: GASTROINTESTINAL | ||||||
| 12/10/2020 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $30.43 | General |
| Category: GASTROINTESTINAL | ||||||
| 10/01/2020 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: Diabetes | ||||||
| 09/02/2020 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $13.47 | General |
| Category: GASTROINTESTINAL | ||||||
| 09/01/2020 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: Diabetes | ||||||
| 06/29/2020 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $13.12 | General |
| Category: Diabetes | ||||||
| 06/23/2020 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $11.45 | General |
| Category: GASTROINTESTINAL | ||||||
| 04/28/2020 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS, Tresiba | Food and Beverage | In-kind items and services | $15.31 | General |
| Category: Diabetes | ||||||
| 01/31/2020 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: GASTROINTESTINAL | ||||||
| 12/19/2019 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: GASTROINTESTINAL | ||||||
| 10/24/2019 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $12.29 | General |
| Category: GASTROINTESTINAL | ||||||
| 08/15/2019 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: GASTROINTESTINAL | ||||||
| 12/20/2018 | PFIZER INC. | LYRICA (Drug), EUCRISA, COLOGUARD | Food and Beverage | In-kind items and services | $1.03 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
| 11/13/2018 | PFIZER INC. | LYRICA (Drug), EUCRISA, COLOGUARD | Food and Beverage | In-kind items and services | $1.49 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 953 | 2,308 | $294,018 | $148,978 |
| 2022 | 24 | 1,292 | 2,959 | $327,689 | $184,055 |
| 2021 | 28 | 1,571 | 3,541 | $401,829 | $237,941 |
| 2020 | 33 | 2,038 | 4,553 | $493,695 | $284,681 |
Total Patients
5,854
Total Services
13,361
Medicare Billing
$855,654
Procedure Codes
107
All Medicare Procedures & Services
107 procedure records from CMS Medicare Utilization — Page 3 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Office | 2021 | 88 | 281 | $21,075 | $15,073 | 71.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 74 | 92 | $21,019 | $13,686 | 65.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 105 | 105 | $13,125 | $13,036 | 99.3% |
| 99306 | Initial nursing facility visit, typically 45 minutes per day | Office | 2021 | 79 | 82 | $14,350 | $10,661 | 74.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 101 | 123 | $14,896 | $10,087 | 67.7% |
| 99305 | Initial nursing facility visit, typically 35 minutes per day | Office | 2021 | 68 | 73 | $11,680 | $7,190 | 61.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 44 | 78 | $8,646 | $6,068 | 70.2% |
| 99307 | Subsequent nursing facility visit, typically 10 minutes per day | Office | 2021 | 56 | 165 | $8,250 | $5,617 | 68.1% |
| 99496 | Transitional care management services, highly complexity, requiring face-to-face visits within 7 days of discharge | Office | 2021 | 21 | 27 | $6,345 | $5,076 | 80.0% |
| 99318 | Nursing facility annual assessment, typically 30 minutes | Office | 2021 | 45 | 45 | $4,950 | $3,205 | 64.8% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2021 | 11 | 11 | $1,925 | $1,797 | 93.3% |
| 20611 | Aspiration and/or injection of major joint or joint capsule with recording and reporting using ultrasound guidance | Office | 2021 | 19 | 31 | $3,100 | $1,679 | 54.2% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 42 | 139 | $4,200 | $1,429 | 34.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 18 | 18 | $1,561 | $968.55 | 62.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 13 | 13 | $3,120 | $958.50 | 30.7% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Office | 2021 | 12 | 12 | $1,200 | $849.36 | 70.8% |
| 99217 | Hospital observation care on day of discharge | Facility | 2021 | 12 | 12 | $1,038 | $605.52 | 58.3% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2021 | 35 | 45 | $225.00 | $180.90 | 80.4% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 17 | 17 | $680.00 | $172.05 | 25.3% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2021 | 20 | 83 | $830.00 | $122.38 | 14.7% |
| 85651 | Red blood cell sedimentation rate, to detect inflammation, non-automated | Office | 2021 | 11 | 12 | $72.00 | $51.24 | 71.2% |
| 81002 | Urinalysis, manual test | Office | 2021 | 12 | 12 | $120.00 | $41.76 | 34.8% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2021 | 14 | 86 | $176.00 | $9.91 | 5.6% |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | Office | 2021 | 23 | 29 | $58.00 | $0.59 | 1.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 221 | 867 | $151,655 | $63,244 | 41.7% |
About Dr. Mohammad Kalo, M.D
Dr. Mohammad Kalo, M.D is a Internal Medicine healthcare provider based in Wheelersburg, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750305538.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mohammad Kalo, M.D has received a total of $1,002 in payments from pharmaceutical and medical device companies, with $29.96 received in 2024. These payments were reported across 55 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($1,001).
As a Medicare-enrolled provider, Kalo has provided services to 5,854 Medicare beneficiaries, totaling 13,361 services with total Medicare billing of $855,654. Data is available for 4 years (2020–2023), covering 107 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Wheelersburg, OH
- Active Since 07/26/2006
- Last Updated 02/20/2013
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1750305538
Products in Payments
- LYRICA (Drug) $176.00
- Rybelsus (Drug) $122.16
- COLOGUARD (Device) $121.76
- RYBELSUS (Drug) $112.69
- JARDIANCE (Drug) $111.85
- Kerendia (Drug) $106.65
- Ozempic (Drug) $69.35
- Otezla (Drug) $36.89
- Repatha (Biological) $30.91
- COLOGUARD DNA CAPTURE REAGENTS (Device) $24.16
- RELISTOR (Drug) $15.71
- Victoza (Drug) $13.93
- EMBEDA (Drug) $13.91
- LINZESS (Drug) $11.98
- NAMZARIC (Drug) $10.63
- GEMTESA (Drug) $0.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.